皇冠官网(www.huangguan.us)是皇冠体育官方信用网线上直营平台。皇冠官网开放信用网和现金网代理申请、信用网和现金网会员注册、线上充值线上投注、线上提现、皇冠官方APP下载等业务。

首页社会正文

足球分析师(www.99cx.vip):Sanofi ends cancer drug trials

admin2022-08-264

足球分析师www.99cx.vip)是一个开放皇冠体育网址代理APP下载、皇冠体育网址会员APP下载、皇冠体育网址线路APP下载、皇冠体育网址登录APP下载的官方平台。足球分析师上足球分析专家数据更新最快。足球分析师开放皇冠官方会员注册、皇冠官方代理开户等业务。

The decision to stop all studies with amcenestrant follows an analysis of late-stage trial data evaluating the drug in patients with a type of breast cancer, the company said in a statement yesterday.

PARIS: Sanofi is ending development of a key cancer medicine in a blow to the French drugmaker’s pipeline of experimental therapies.

The decision to stop all studies with amcenestrant follows an analysis of late-stage trial data evaluating the drug in patients with a type of breast cancer, the company said in a statement yesterday.

The move leaves Sanofi even more dependent for growth on blockbuster Dupixent, an antibody treatment for ailments ranging from asthma to severe eczema.

The company’s slate of experimental medicines has faced other setbacks, including safety concerns regarding multiple sclerosis treatment tolebrutinib.

,

新2信用网出租www.hg108.vip)是新2(正网)接入菜宝钱包的TRC20-USDT支付系统,为新2代理提供专业的网上运营管理系统。新2信用网出租系统实现注册、充值、提现、客服等全自动化功能。采用的USDT匿名支付、阅后即焚的IM客服系统,让新2代理的运营更轻松更安全。

,

Sanofi has included both amcenestrant and tolebrutinib as among six products in its pipeline that it prioritised as “potentially transformative” treatments.

Some investors are questioning the company’s growth trajectory after both of those medicines encountered problems.

UBS analysts last week downgraded Sanofi, saying there are few major catalysts coming soon to drive more excitement to the stock. — Bloomberg


转载说明:本文转载自Sunbet。

网友评论